Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients
Cytokine, Volume 63, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Egypt has the highest prevalence of hepatitis C virus infection worldwide. CXCL10 is a potent chemoattractant that directs effector lymphocytes to sites of inflammation. It has been reported that plasma CXCL10 is processed by dipeptidylpeptidase IV (DPPIV) thus leading to the generation of an antagonist form. Using Luminex-based immunoassays we determined the concentration of different forms of CXCL10 (total, agonist, and antagonist). We also evaluated plasma soluble DPPIV (sDPPIV) concentration and plasma dipeptidylpeptidase (DPP) activity. Using flow cytometry and immunohistochemistry, we analyzed the distribution of lymphocyte subsets. Plasma CXCL10 was elevated in chronic HCV patients, however the agonist form was undetectable. Increased sDPPIV concentration and DPP activity supported the NH2-truncation of CXCL10. Finally, we demonstrated an increased frequency of CXCR3+ cells in the peripheral blood, and low numbers of CXCR3+ cells within the lobular regions of the liver. These findings generalize the observation of chemokine antagonism as a mechanism of immune modulation in chronic HCV patients and may help guide the use of new therapeutic immune modulators. © 2013 Elsevier Ltd.
Authors & Co-Authors
Ragab, Dina
France, Paris
Institut Pasteur, Paris
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Laird, Melissa E.
France, Paris
Institut Pasteur, Paris
France, Paris
Inserm
Duffy, Darragh
France, Paris
Institut Pasteur, Paris
France, Paris
Inserm
Casrouge, Armanda
France, Paris
Institut Pasteur, Paris
France, Paris
Inserm
Mamdouh, Rasha
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Abass, Amal
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Shenawy, Dina E.
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Shebl, Abdelhadi Mohamed
Egypt, Mansoura
Mansoura University
Elkashef, Wagdi Fawzi
Egypt, Mansoura
Mansoura University
Zalata, Khaled Refaat
Egypt, Mansoura
Mansoura University
Kamal, Mostafa
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Egypt, Cairo
National Hepatology and Tropical Medicine Research Institute Nhtmri
Esmat, Gamal
Egypt, Cairo
National Hepatology and Tropical Medicine Research Institute Nhtmri
Egypt, Cairo
Faculty of Medicine
Bonnard, P.
France, Paris
Hôpital Tenon
Fontanet, A. L.
France, Paris
Institut Pasteur, Paris
France, Paris
Conservatoire National Des Arts et Metiers
Rafik, Mona M.
Egypt, Cairo
Faculty of Medicine - Ain Shams University
Albert, Matthew L.
France, Paris
Institut Pasteur, Paris
France, Paris
Inserm
France, Paris
Université Paris Cité
Statistics
Citations: 28
Authors: 16
Affiliations: 9
Identifiers
Doi:
10.1016/j.cyto.2013.04.016
ISSN:
10434666
e-ISSN:
10960023
Research Areas
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Egypt